Canada's generic semaglutide prices to step down to 35% of brand with three sellers

Canada's generic semaglutide prices will fall on a fixed schedule tied to how many manufacturers are selling the drug, under the country's pan-Canadian Pharmaceutical Alliance pricing framework. Once three or more generics are on the market, the price drops to 35% of the brand list price ^[1][2]. Applied to current Canadian brand prices, that works out to roughly C$100 a month out of pocket ^[2].

How the steps work

Under the framework, the first generic entrant prices at 75% to 85% of the brand list price ^[1]. A separate account of the same framework, from pharmacist and drug policy researcher Mina Tadrous of the University of Toronto, puts the first entrant at 75% of the brand list price, the second at about 50%, and three or more at 35% ^[2]. The two descriptions of the first-entrant tier do not match exactly.

The steps are tied to the number of manufacturers on the market rather than negotiated product by product ^[2].

Canada's brand prices give those percentages something to work from. Pharmacy prices tracked in Canada range from C$86.40 to C$663 for Ozempic and C$270 to C$550 for Wegovy ^[2]. Tadrous told The BMJ that once three generics are selling, out-of-pocket costs should reach around C$100 a month ^[2].

How Canada got here

Two events opened the market. Novo Nordisk stopped paying a C$250 annual patent maintenance fee in 2018, and a separate regulatory approval requirement expired on January 5, 2026 ^[2]. Dr. Reddy's generic semaglutide became available in Canada on May 15, 2026, while Apotex has not announced a release date ^[2].

Counts of how many generics are authorized differ. One report says Health Canada has authorized two generic semaglutide injections, from Dr. Reddy's and Apotex, with seven applications still under review ^[2]. A running approval count lists three of nine generic semaglutide products approved by Health Canada ^[1].

Why it matters for patients

The tiers apply in Canada, not the United States. Novo Nordisk told the BBC the Canadian situation is "a localized situation based on our specific patent timelines and regulatory environment and does not reflect the situation in the United States, where exclusivity remains intact" ^[2]. Patent protection for semaglutide runs to 2032 in the United States and 2033 in Europe and Japan ^[2]. No comparable US step-down schedule for generic semaglutide has been reported.

Canadians choosing between brand and generic also face a marketing push. Novo Nordisk is offering discount cards to cover the cost gap and running ads encouraging patients to ask for brand-name Ozempic, and Tadrous said he expects the company to hold more market share after generic entry than is typical ^[2].

Competition in this drug class is not limited to semaglutide. Mounjaro and Zepbound, both tirzepatide, are projected to overtake semaglutide as the leading GLP-1 products within a few years, per The BMJ ^[2].

What happens next

A third entrant is the trigger for the 35% tier ^[1][2]. Sandoz is targeting the third quarter of 2026 for its own generic semaglutide ^[1], though no approval or launch date has been confirmed. Canadian benefits plans are preparing for a 65% cut to the list price once a third generic launches ^[1], which is the same figure as the 35% tier viewed from the other side.

Novo Nordisk has forecast a 5% to 13% decline in 2026 sales, and its share price fell 17% on the day the guidance was announced ^[2]. CEO Mike Doustdar described 2026 as "a year of unprecedented pricing pressure" ^[2].